Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

PHASE3CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions
Contraception
Interventions
DRUG

BAY86-5300

0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function

DRUG

BAY86-5300

0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support

Trial Locations (43)

14004

Córdoba

20154

Milan

20357

Hamburg

25123

Brescia

27100

Pavia

28660

Boadilla del Monte

29013

Málaga

31000

Toulouse

38889

Blankenburg

39130

Magdeburg

39288

Burg

40138

Bologna

41124

Modena

42103

Wuppertal

45160

Olivet

53100

Siena

54000

Nancy

56126

Pisa

60590

Frankfurt am Main

64200

Biarritz

69115

Heidelberg

75007

Paris

75018

Paris

78160

Marly-le-Roi

80138

Napoli

90127

Palermo

95123

Catania

75 009

Paris

75 017

Paris

67 000

Strasbourg

07545

Gera

07768

Kahla

09124

Cagliari

00189

Roma

03600

Elda

08019

Barcelona

S40 4TF

Chesterfield

NG2 4PJ

Nottingham

BA1 2SR

Bath

KT24 6QT

East Horsley

BA15 1DQ

Bradford-on-Avon

SN3 9DL

Corsham

CF5 4AD

Cardiff

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY